{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:17:41Z","timestamp":1788985061934,"version":"build-2803163510"},"reference-count":154,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccination remains one of the most effective strategies for preventing infectious diseases. Yet, the success of modern vaccines increasingly depends on the rational design of adjuvants that enhance and shape immune responses. In this review, we examine current and emerging adjuvant strategies for viral vaccines across the human lifespan. Traditional adjuvants, particularly aluminum salts, have long served as the foundation of vaccine formulations. Still, their limitations have driven the exploration of novel platforms, including emulsions, nucleic acid-based adjuvants, and advanced particulate delivery platforms with intrinsic immunostimulatory properties. These newer approaches act through diverse mechanisms, such as activating innate immune pathways via pattern recognition receptors (PRRs) and stimulating antigen-presenting cells (APCs), thereby improving both humoral and cellular immunity. Recent advances in molecular biology, nanotechnology, and systems vaccinology have deepened mechanistic understanding and enabled more precise modulation of immune responses. However, significant challenges remain, including incomplete knowledge of adjuvant mechanisms, limited diversity among licensed adjuvants, safety concerns, and inconsistent efficacy across age groups. In particular, immune immaturity in infants and immunosenescence in older adults highlight the need for age-specific adjuvant strategies. The review identifies critical gaps in comparative studies, long-term safety data, and the development of adjuvants capable of inducing broad and durable immunity. Further, this article integrates licensed and emerging viral vaccine adjuvants through a lifespan framework. Addressing these limitations through interdisciplinary research and precision-based approaches will be essential for advancing next-generation vaccines and improving global preparedness for emerging infectious diseases.<\/jats:p>","DOI":"10.3390\/vaccines14060508","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:23:21Z","timestamp":1780622601000},"page":"508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Viral Vaccine Adjuvant Strategies for Shaping Durable Immunity Across the Human Lifespan"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-1327","authenticated-orcid":false,"given":"Swarandeep","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7469-4450","authenticated-orcid":false,"given":"Surabhi","family":"Gautam","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322, USA"},{"name":"Department of Orthopedics, Emory Musculoskeletal Institute, Emory University School of Medicine, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhi","family":"Thakkar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8181-3999","authenticated-orcid":false,"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[{"name":"ICGEB-Emory Vaccine Program, International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-7725","authenticated-orcid":false,"given":"Devyani","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/irv.12591","article-title":"Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses","volume":"12","author":"Trombetta","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Montgomery, L., and Larbi, A. (2025). Monitoring Immune Responses to Vaccination: A Focus on Single-Cell Analysis and Associated Challenges. Vaccines, 13.","DOI":"10.3390\/vaccines13040420"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41541-022-00596-5","article-title":"Factors influencing long-term persistence of anti-HBs after hepatitis B vaccination","volume":"7","author":"Fonzo","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Antia, A., Ahmed, H., Handel, A., Carlson, N.E., Amanna, I.J., Antia, R., and Slifka, M. (2018). Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biol., 16.","DOI":"10.1371\/journal.pbio.2006601"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2214-109X(23)00556-9","article-title":"Long-term immunity following yellow fever vaccination: A systematic review and meta-analysis","volume":"12","author":"Schnyder","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"ofz144","DOI":"10.1093\/ofid\/ofz144","article-title":"Long-term antibody persistence after hepatitis E virus infection and vaccination in Dongtai, China","volume":"6","author":"Kmush","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.coi.2009.05.019","article-title":"Human B cell memory","volume":"21","author":"Lanzavecchia","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/bloodadvances.2017004481","article-title":"Long-lived plasma cells in human bone marrow can be either CD19+ or CD19\u2212","volume":"1","author":"Brynjolfsson","year":"2017","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e202101285","DOI":"10.26508\/lsa.202101285","article-title":"Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting","volume":"5","author":"Joyner","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41590-022-01340-w","article-title":"The secret to longevity, plasma cell style","volume":"23","author":"Tellier","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lightman, S.M., Utley, A., and Lee, K.P. (2019). Survival of long-lived plasma cells (LLPC): Piecing together the puzzle. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00965"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41591-024-03278-y","article-title":"SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination","volume":"31","author":"Nguyen","year":"2025","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.it.2009.09.002","article-title":"Neonatal immunity: Faulty T-helpers and the shortcomings of dendritic cells","volume":"30","author":"Zaghouani","year":"2009","journal-title":"Trends Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3389\/fimmu.2018.03123","article-title":"Understanding the functional properties of neonatal dendritic cells: A doorway to enhance vaccine effectiveness?","volume":"9","author":"Papaioannou","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41385-019-0234-5","article-title":"Type I IFN ineffectively activates neonatal dendritic cells limiting respiratory antiviral T-cell responses","volume":"13","author":"Turfkruyer","year":"2020","journal-title":"Mucosal Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1753425918771178","article-title":"TLR agonist combinations that stimulate Th type I polarizing responses from human neonates","volume":"24","author":"Surendran","year":"2018","journal-title":"Innate Immun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Pereira, B., Xu, X.-N., and Akbar, A.N. (2020). Targeting inflammation and immunosenescence to improve vaccine responses in the elderly. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.583019"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e71119","DOI":"10.1002\/hsr2.71119","article-title":"Immune aging, immunosenescence, and inflammaging: Implications for vaccine response in older adults","volume":"8","author":"Falahi","year":"2025","journal-title":"Health Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2477300","DOI":"10.1080\/07853890.2025.2477300","article-title":"Age-related changes in the immune system and challenges for the development of age-specific vaccines","volume":"57","author":"Doherty","year":"2025","journal-title":"Ann. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41590-024-02036-z","article-title":"System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans","volume":"26","author":"Cortese","year":"2025","journal-title":"Nat. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1016\/j.cell.2021.05.039","article-title":"The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination","volume":"184","author":"Wimmers","year":"2021","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1038\/s41590-025-02309-1","article-title":"Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates","volume":"26","author":"Akhtar","year":"2025","journal-title":"Nat. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","article-title":"Adjuvant system AS01: From mode of action to effective vaccines","volume":"23","author":"Roman","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Cusimano, G., Staupe, R.P., and Sullivan, N.L. (2026). Emerging novel methodologies to understand and strategically target long-lived plasma cells in vaccine design to induce durable immunity. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1680375"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Koike, T., and Ise, W. (2025). Developmental trajectory of long-lived plasma cells. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1684210"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41423-023-01095-w","article-title":"B-cell and antibody responses to SARS-CoV-2: Infection, vaccination, and hybrid immunity","volume":"21","author":"Lapuente","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Auladell, M., Jia, X., Hensen, L., Chua, B., Fox, A., Nguyen, T.H.O., Doherty, P.C., and Kedzierska, K. (2019). Recalling the future: Immunological memory toward unpredictable influenza viruses. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01400"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13263","DOI":"10.1073\/pnas.230417497","article-title":"Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs","volume":"97","author":"Ochsenbein","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yan, L.-N., Liu, P.-P., Li, X.-G., Zhou, S.-J., Li, H., Wang, Z.-Y., Shen, F., Lu, B.-C., Long, Y., and Xiao, X. (2022). Neutralizing antibodies and cellular immune responses against SARS-CoV-2 sustained one and a half years after natural infection. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.803031"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e02127-19","DOI":"10.1128\/JVI.02127-19","article-title":"Persistence of varicella-zoster virus-specific plasma cells in adult human bone marrow following childhood vaccination","volume":"94","author":"Eberhardt","year":"2020","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(01)79001-3","article-title":"Neutralizing antiviral antibody responses","volume":"79","author":"Zinkernagel","year":"2001","journal-title":"Adv. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-L\u00e1zaro, D., Garrosa, M., S\u00e1nchez-Serrano, N., Garrosa, E., Jim\u00e9nez-Callejo, E., Yanguas, M.D.P., Mielgo-Ayuso, J., and Seco-Calvo, J. (2022). Effectiveness of Comirnaty\u00ae Vaccine and Correlates of Immunogenicity and Adverse Reactions: A Single-Center Prospective Case Series Study. Vaccines, 10.","DOI":"10.3390\/vaccines10081170"},{"key":"ref_36","first-page":"CD004407","article-title":"Vaccines for measles, mumps, rubella, and varicella in children","volume":"11","author":"Rivetti","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cyto.2014.06.003","article-title":"TLR-mediated inflammatory response to neonatal pathogens and co-infection in neonatal immune cells","volume":"69","author":"Sugitharini","year":"2014","journal-title":"Cytokine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.4049\/jimmunol.0901481","article-title":"Neonatal innate TLR-mediated responses are distinct from those of adults","volume":"183","author":"Kollmann","year":"2009","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1038\/s41598-018-28111-8","article-title":"Age-related differences in humoral and cellular immune responses after primary immunisation: Indications for stratified vaccination schedules","volume":"8","author":"Wagner","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Nguyen, M., Leuridan, E., Zhang, T., De Wit, D., Willems, F., Van Damme, P., Goldman, M., and Goriely, S. (2010). Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010407"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2249.2005.02928.x","article-title":"Cytokine responses correlate differentially with age in infancy and early childhood","volume":"142","author":"Adam","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00281-017-0654-9","article-title":"Vaccine responses in newborns","volume":"39","author":"Saso","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2249.2002.01873.x","article-title":"Down-regulation of Th1 responses in human neonates","volume":"128","author":"Marodi","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.it.2014.04.007","article-title":"Ontogeny of early life immunity","volume":"35","author":"Dowling","year":"2014","journal-title":"Trends Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.vaccine.2012.10.016","article-title":"Immune response to vaccine adjuvants during the first year of life","volume":"31","author":"Levy","year":"2013","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses","volume":"22","author":"Mogensen","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/JLB.5A0521-242R","article-title":"Cytosolic dsRNA improves neonatal innate immune responses to adjuvants in use in pediatric vaccines","volume":"112","author":"Brennan","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.amjms.2021.03.003","article-title":"Bacillus Calmette-Guerin vaccine and nonspecific immunity","volume":"361","author":"Parmar","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trivac.2013.11.004","article-title":"Neonatal BCG vaccination is associated with enhanced T-helper 1 immune responses to heterologous infant vaccines","volume":"3","author":"Libraty","year":"2014","journal-title":"Trials Vaccinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/cid\/ciae537","article-title":"Long-term dynamics of measles virus\u2013specific neutralizing antibodies in children vaccinated before 12 months of age","volume":"80","author":"Hulscher","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1086\/522519","article-title":"Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life","volume":"196","author":"Nair","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1097\/INF.0000000000002727","article-title":"Immunogenicity and safety of an MF59-adjuvanted quadrivalent seasonal influenza vaccine in young children at high risk of influenza-associated complications: A Phase III, randomized, observer-blind, multicenter clinical trial","volume":"39","author":"Esposito","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1016\/j.vaccine.2018.08.032","article-title":"Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-na\u00efve children in a randomized clinical trial in rural Senegal","volume":"36","author":"Diallo","year":"2018","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Bansal, A., Trieu, M.C., Mohn, K.G.I., and Cox, R.J. (2021). Safety, immunogenicity, efficacy and effectiveness of inactivated influenza vaccines in healthy pregnant women and children under 5 years: An evidence-based clinical review. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.744774"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2425149","DOI":"10.1080\/21645515.2024.2425149","article-title":"Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6\u201335 months of age in China: A randomized, double-blind, clinical trial","volume":"20","author":"Wang","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1016\/j.vaccine.2022.02.088","article-title":"Efficacy and safety of a quadrivalent influenza vaccine in children aged 6\u201335 months: A global, multiseasonal, controlled, randomized Phase III study","volume":"40","author":"Esposito","year":"2022","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.vaccine.2013.07.007","article-title":"Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial","volume":"31","author":"Yang","year":"2013","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Huang, N., Chi, H., and Qiao, J. (2020). Role of regulatory T cells in regulating fetal-maternal immune tolerance in healthy pregnancies and reproductive diseases. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01023"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Krop, J., Heidt, S., Claas, F.H.J., and Eikmans, M. (2020). Regulatory T cells in pregnancy: It is not all about FoxP3. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01182"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/humupd\/dmp004","article-title":"Regulatory T-cells and immune tolerance in pregnancy: A new target for infertility treatment?","volume":"15","author":"Guerin","year":"2009","journal-title":"Hum. Reprod. Update"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wilcox, C.R., Holder, B., and Jones, C.E. (2017). Factors affecting the FcRn-mediated transplacental transfer of antibodies and implications for vaccination in pregnancy. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01294"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gao, C., Chen, Q., Hao, X., and Wang, Q. (2023). Immunomodulation of antibody glycosylation through the placental transfer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316772"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/AOG.0000000000001066","article-title":"Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy","volume":"126","author":"Sukumaran","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_65","first-page":"e68349","article-title":"Use of the Abrysvo Vaccine in Pregnancy to Prevent Respiratory Syncytial Virus in Infants: A Review","volume":"16","author":"Patel","year":"2024","journal-title":"Cureus"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"127868","DOI":"10.1016\/j.vaccine.2025.127868","article-title":"Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus disease burden in early life: A scoping review of dynamic modelling studies","volume":"68","author":"Bicego","year":"2025","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial","volume":"145","author":"Pahud","year":"2025","journal-title":"Obstet. Gynecol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"100988","DOI":"10.37349\/eaa.2025.100988","article-title":"Maternal RSV vaccination to protect infants: Current evidence and future directions","volume":"3","author":"Sallam","year":"2025","journal-title":"Explor. Asthma Allergy"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41590-024-01971-1","article-title":"Regulators of placental antibody transfer through a modeling lens","volume":"25","author":"Wessel","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"177.e1","DOI":"10.1016\/j.ajog.2012.07.007","article-title":"Safety of MF59-adjuvanted A\/H1N1 influenza vaccine in pregnancy: A comparative cohort study","volume":"207","author":"Heikkinen","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.4161\/hv.29393","article-title":"A dose-ranging study of MF59\u00ae-adjuvanted and non-adjuvanted A\/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination","volume":"10","author":"Reisinger","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1742-4933-11-10","article-title":"Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A (H3N2) strains","volume":"11","author":"Camilloni","year":"2014","journal-title":"Immun. Ageing"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ijid.2022.07.048","article-title":"Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: A systematic review and meta-analysis","volume":"122","author":"Domnich","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2024.09.005","article-title":"Trained innate immunity: Concept, nomenclature, and future perspectives","volume":"154","author":"Netea","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102190","DOI":"10.1016\/j.coi.2022.102190","article-title":"Trained immunity: Implications for vaccination","volume":"77","author":"Geckin","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1021\/acsinfecdis.5c00840","article-title":"Trained Immunity Empowers Vaccine Design and Application","volume":"12","author":"Hu","year":"2026","journal-title":"ACS Infect. Dis."},{"key":"ref_77","first-page":"ofaf007","article-title":"BCG-induced DNA methylation changes improve coronavirus disease 2019 vaccine immunity without decreasing the risk for severe acute respiratory syndrome coronavirus 2 infection","volume":"12","author":"Koster","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Xing, J., Zhao, X., Li, X., Fang, R., Sun, M., Zhang, Y., and Song, N. (2025). The recent advances in vaccine adjuvants. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1557415"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2015.11.041","article-title":"Adjuvant-enhanced CD4 T cell responses are critical to durable vaccine immunity","volume":"3","author":"Martins","year":"2016","journal-title":"eBioMedicine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/cid\/ciab121","article-title":"Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: A claims-based cohort study","volume":"73","author":"Sun","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"103241","DOI":"10.1016\/j.eclinm.2025.103241","article-title":"Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: Efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications","volume":"83","author":"Strezova","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/21645515.2017.1373227","article-title":"MF59-adjuvanted influenza vaccine (FLUAD\u00ae) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone\u00ae): A randomized, multicenter, Phase III pediatric trial in Mexico","volume":"14","author":"Patel","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/CVI.00480-10","article-title":"Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A\/H1N1\/2009 influenza virus vaccine administered to adults during two randomized controlled trials","volume":"18","author":"Roman","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_86","first-page":"e00553-16","article-title":"Long-term persistence of cell-mediated and humoral responses to A (H1N1) pdm09 influenza virus vaccines and the role of the AS03 adjuvant system in adults during two randomized controlled trials","volume":"24","author":"Clement","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1080\/21645515.2015.1063754","article-title":"Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A (H1N1) pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies","volume":"11","author":"Aristegui","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14760584.2021.1908133","article-title":"CpG-adjuvanted hepatitis B vaccine (HEPLISAV-B\u00ae) update","volume":"20","author":"Lee","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"ofad267","DOI":"10.1093\/ofid\/ofad267","article-title":"Observational study evaluating the seroprotection of HepB-alum vaccine and HepB-CpG vaccine in people with HIV","volume":"10","author":"Dudzik","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.4049\/jimmunol.173.7.4433","article-title":"Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+ CD25+ regulatory T cells","volume":"173","author":"Moseman","year":"2004","journal-title":"J. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.vaccine.2023.05.001","article-title":"Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial","volume":"41","author":"Kuriyama","year":"2023","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"126777","DOI":"10.1016\/j.vaccine.2025.126777","article-title":"Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review","volume":"49","author":"Gschwend","year":"2025","journal-title":"Vaccine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3018(22)00041-8","article-title":"Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: A randomised, controlled, phase 2A\/2B trial","volume":"9","author":"Madhi","year":"2022","journal-title":"Lancet HIV"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamainternmed.2025.6355","article-title":"Durability of respiratory syncytial virus vaccine effectiveness among US veterans","volume":"186","author":"Bajema","year":"2026","journal-title":"JAMA Intern. Med."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Wilkins, A.L., Kazmin, D., Napolitani, G., Clutterbuck, E.A., Pulendran, B., Siegrist, C.-A., and Pollard, A.J. (2017). AS03- and MF59-Adjuvanted Influenza Vaccines in Children. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01760"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1016\/j.vaccine.2018.06.004","article-title":"A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults","volume":"36","author":"Baay","year":"2018","journal-title":"Vaccine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs","volume":"38","author":"Petrovsky","year":"2015","journal-title":"Drug Saf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"93rv2","DOI":"10.1126\/scitranslmed.3002302","article-title":"Assessing the Safety of Adjuvanted Vaccines","volume":"3","author":"Ahmed","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2189885","DOI":"10.1080\/21645515.2023.2189885","article-title":"The Matrix-M\u2122 adjuvant: A critical component of vaccines for the 21st century","volume":"19","author":"Linda","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cell.2022.01.027","article-title":"Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals","volume":"185","author":"Lederer","year":"2022","journal-title":"Cell"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Facciol\u00e0, A., Visalli, G., Lagana, A., and Di Pietro, A. (2022). An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. Vaccines, 10.","DOI":"10.3390\/vaccines10050819"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e13288","DOI":"10.1111\/irv.13288","article-title":"Relative Effectiveness of the MF59\u00ae-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019\u20132020 US Influenza Season","volume":"18","author":"Imran","year":"2024","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4049\/jimmunol.181.1.17","article-title":"Cutting edge: Inflammasome activation by alum and alum\u2019s adjuvant effect are mediated by NLRP3","volume":"181","author":"Li","year":"2008","journal-title":"J. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/21645515.2019.1666612","article-title":"Long-term persistence of anti-HBs after hepatitis B vaccination among adults: 8-year results","volume":"16","author":"Ren","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"7914","DOI":"10.1073\/pnas.1104588108","article-title":"Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells","volume":"108","author":"MacLeod","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Kurosawa, M., Sekine, M., Yamaguchi, M., Kudo, R., Hanley, S.J.B., Hara, M., Adachi, S., Ueda, Y., Miyagi, E., and Ikeda, S. (2022). Long-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review. Vaccines, 10.","DOI":"10.3390\/vaccines10020256"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.4161\/hv.24715","article-title":"The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV\u2122 review","volume":"9","author":"Eng","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"127362","DOI":"10.1016\/j.vaccine.2025.127362","article-title":"Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19)","volume":"61","author":"McGarry","year":"2025","journal-title":"Vaccine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ccell.2025.12.002","article-title":"Targeting STING to generate therapeutic anti-tumor immunity","volume":"44","author":"Fahey","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Shen, Y., Huang, W., Nie, J., and Zhang, L. (2025). Progress update on STING agonists as vaccine adjuvants. Vaccines, 13.","DOI":"10.3390\/vaccines13040371"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/15476286.2024.2333123","article-title":"mRNA vaccine designs for optimal adjuvanticity and delivery","volume":"21","author":"Mochida","year":"2024","journal-title":"RNA Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1016\/j.ymthe.2025.09.011","article-title":"Immunology of RNA-based vaccines: The critical interplay between inflammation and expression","volume":"33","author":"Tregoning","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"eadu8067","DOI":"10.1126\/scitranslmed.adu8067","article-title":"The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins","volume":"17","author":"Kumar","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1002\/mco2.238","article-title":"Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4\/5-included SARS-CoV-2 variants than homologous vaccination of mRNA vaccine","volume":"4","author":"Peng","year":"2023","journal-title":"MedComm"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/imr.13115","article-title":"COVID-19 and plasma cells: Is there long-lived protection?","volume":"309","author":"Nguyen","year":"2022","journal-title":"Immunol. Rev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1016\/j.vaccine.2023.10.055","article-title":"Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda","volume":"41","author":"Mustapher","year":"2023","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-022-00477-x","article-title":"Therapeutic efficacy of an Ad26\/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques","volume":"7","author":"Ventura","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Lykins, W.R., and Fox, C.B. (2023). Practical Considerations for Next-Generation Adjuvant Development and Translation. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071850"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/2213529402666160601125159","article-title":"Targeting pattern recognition receptors (PRRs) in nano-adjuvants: Current perspectives","volume":"2","author":"Haghparast","year":"2016","journal-title":"Curr. Bionanotechnol. (Discontin.)"},{"key":"ref_128","first-page":"779","article-title":"Novel adjuvants & delivery vehicles for vaccines development: A road ahead","volume":"138","author":"Mohan","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imm.13012","article-title":"Systems vaccinology and big data in the vaccine development chain","volume":"156","author":"Raeven","year":"2019","journal-title":"Immunology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coi.2020.05.001","article-title":"Emerging technologies for systems vaccinology\u2014Multi-omics integration and single-cell (epi)genomic profiling","volume":"65","author":"Wimmers","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Wrona, M.V., Ghosh, R., Coll, K., Chun, C., and Yousefzadeh, M.J. (2024). The 3 I\u2019s of immunity and aging: Immunosenescence, inflammaging, and immune resilience. Front. Aging, 5.","DOI":"10.3389\/fragi.2024.1490302"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Ferrari, F.A., Ciminello, E., Ceccaroni, M., Pavone, M., Di Donato, V., Perniola, G., Panici, P.B., Muzii, L., Giannini, A., and Vizzielli, G. (2025). No increased risk of autoimmune diseases following HPV vaccination: A systematic review and meta-analysis. Vaccines, 13.","DOI":"10.3390\/vaccines13040391"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Poder, A., Oberije, J., Meyer, J., Heymer, P., Molrine, D., Versage, E., Isakov, L., Zhang, Q., and Hohenboken, M. (2023). Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine compared with a nonadjuvanted, quadrivalent influenza vaccine in adults 50\u201364 years of age. Vaccines, 11.","DOI":"10.3390\/vaccines11101528"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barr\u00e9 syndrome following recombinant zoster vaccine in Medicare beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","article-title":"Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: A pooled post-hoc analysis of two parallel randomized trials","volume":"15","author":"Oostvogels","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1016\/j.vaccine.2019.06.039","article-title":"An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A (H1N1) pdm09 vaccines","volume":"37","author":"Hauser","year":"2019","journal-title":"Vaccine"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Domnich, A., Trombetta, C.S., Fallani, E., and Salvatore, M. (2024). Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0310677"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1542\/peds.2009-2628","article-title":"Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence","volume":"126","author":"Vesikari","year":"2010","journal-title":"Pediatrics"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/21645515.2015.1043501","article-title":"Safety assessment of adjuvanted vaccines: Methodological considerations","volume":"11","author":"Yarzabal","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.vaccine.2015.12.024","article-title":"A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children","volume":"34","author":"Stassijns","year":"2016","journal-title":"Vaccine"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciz770","article-title":"Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine","volume":"70","author":"Levin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2009.02.004","article-title":"MF59-adjuvanted influenza vaccine (FLUAD) in children: Safety and immunogenicity following a second year seasonal vaccination","volume":"27","author":"Vesikari","year":"2009","journal-title":"Vaccine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1093\/cid\/ciac302","article-title":"Precision Vaccine Adjuvants for Older Adults: A Scoping Review","volume":"75","author":"Nanishi","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"20200103","DOI":"10.1002\/VIW.20200103","article-title":"Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy","volume":"3","author":"Chen","year":"2022","journal-title":"VIEW"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40264-020-00984-7","article-title":"Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines","volume":"43","author":"Arlegui","year":"2020","journal-title":"Drug Saf."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2351584","DOI":"10.1080\/21645515.2024.2351584","article-title":"Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults \u2265 50 years: A randomized, placebo-controlled trial","volume":"20","author":"Zhu","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2517137","DOI":"10.1080\/10717544.2025.2517137","article-title":"Advances in vaccine adjuvant development and future perspectives","volume":"32","author":"Sinani","year":"2025","journal-title":"Drug Deliv."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41541-023-00759-y","article-title":"Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen","volume":"8","author":"Thomas","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Chew, K., Lee, B., Haren, S.D., Nanishi, E., O\u2019Meara, T., Splaine, J.B., DeLeon, M., Soni, D., Seo, H.S., and Dhe-Paganon, S. (2022). Adjuvant Discovery via a High Throughput Screen using Human Primary Mononuclear Cells. bioRxiv, preprint.","DOI":"10.1101\/2022.06.17.496630"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"109847","DOI":"10.1016\/j.surg.2025.109847","article-title":"Research advances in stimulator of interferon genes (STING) agonists for cancer immunotherapy","volume":"190","author":"Shen","year":"2026","journal-title":"Surgery"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/med.22016","article-title":"cGAS-STING pathway agonists are promising vaccine adjuvants","volume":"44","author":"Tian","year":"2024","journal-title":"Med. Res. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jgs.19243","article-title":"Vaccinations in older adults: Optimization, strategies, and latest guidelines","volume":"73","author":"Pangilinan","year":"2025","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"De Lima Coelho, N.S., and De Lima Coelho, V.S. (2026). From empirical vaccinology to predictive systems-based vaccine design: Multi-omics integration, artificial intelligence, and global equity challenges. Front. Syst. Biol., 6.","DOI":"10.3389\/fsysb.2026.1819469"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41540-025-00592-0","article-title":"Enhancing randomized clinical trials with digital twins","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"npj Syst. Biol. Appl."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:40:42Z","timestamp":1780980042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":154,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["vaccines14060508"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14060508","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}